Eli Lilly & Co., the drugmaker projected to hit a six-year low in revenue this year, reported profit that beat analysts’ estimates as sales gains in other products blunted a decline for its top-seller, Cymbalta.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. Chief Executive Officer John Lechleiter plans to tell a technology conference today.
Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.
Eli Lilly & Co. Chief Executive Officer John Lechleiter said rising sales of the antidepressant Cymbalta and animal drugs stemmed losses from generic competition, helping the company’s earnings beat estimates.
Eli Lilly & Co., the maker of the antidepressant Cymbalta and diabetes treatment Humalog, raised its full-year forecast after second-quarter sales grew faster than expected and cost-cutting programs took effect.